Hepion Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Hepion Pharmaceuticals generated cash of -$40,888,878, which is less than the previous year. Cash used in financing activities reached the amount of $4,494,950 last year. Net change in cash is therefore -$36,403,208.
Cash Flow
| 2016 | -16.55M | -502.20K | 19.89M |
|---|---|---|---|
| 2017 | -8.20M | -2 | 1.18M |
| 2018 | -15.64M | 900 | 12.52M |
| 2019 | -7.56M | -51.46K | 18.70M |
| 2020 | -16.16M | -85.78K | 43.05M |
| 2021 | -31.22M | -130.40K | 81.97M |
| 2022 | -34.96M | -14.07K | -5.13M |
| 2023 | -40.88M | -14.30K | 4.49M |
HEPA Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 51.18M | 91.34M | 40.72M | 13.92M | 2.83M | 5.95M | 7.40M | 4.56M |
Operating activities | ||||||||
Net income | -48.92M | -42.20M | -32.72M | -20.35M | -7.03M | -9.44M | -15.02M | -16.99M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 67.13K | 77.46K | 86.07K | 34.51K | 26.73K | 18.78K | 21.93K | 21.52K |
Stock-based compensation expense | 1.34M | 2.55M | 4.66M | 2.37M | 66.17K | 0 | 1.57K | 901.86K |
| Deferred income tax benefit | 1.34M | 2.55M | 4.66M | 2.37M | 66.17K | 0 | 1.57K | 901.86K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 302.91K | 2.24M | -1.06M | 3.03M | -317.04K | 0 | -111.20K | 0 |
Cash generated by operating activities | -40.88M | -34.96M | -31.22M | -16.16M | -7.56M | -15.64M | -8.20M | -16.55M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -14.30K | -16.33K | -130.40K | -87.98K | -51.46K | 0 | -2 | -6.60K |
Acquisitions Net | 0 | 2.26K | 0 | 2.19K | 0 | 0 | 0 | -495.60K |
Cash generated by investing activities | -14.30K | -14.07K | -130.40K | -85.78K | -51.46K | 900 | -2 | -502.20K |
Financing activities | ||||||||
Common Stock Issued | 4.49M | 17.86M | 82.15M | 42.86M | 7.68M | 1.63M | 1.18M | 19.89M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -21M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -176.58K | -176.58K | -1.11M | -668.94K | 0 | 0 |
Cash used in financing activities | 4.49M | -5.13M | 81.97M | 43.05M | 18.70M | 12.52M | 1.18M | 19.89M |
Net Change In Cash | -36.40M | -40.15M | 50.62M | 26.80M | 11.09M | -3.12M | -1.44M | 2.84M |
Cash at end of period | 14.78M | 51.18M | 91.34M | 40.72M | 13.92M | 2.83M | 5.95M | 7.40M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |